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Recent genomic research increases our understanding of the
causes of complex diseases and strengthens the evidence that
many complex diseases, even those with late age of onset, are
caused in part by genetically induced, adverse prenatal envi-
ronments. This special issue of the Journal of Biomedicine
and Biotechnology speciﬁcally examines the evidence that
gene-gene interactions during early development inﬂuence
human traits and diseases.
Mothers largely determine the fetal environment; there-
fore the maternal genotypes are expected to inﬂuence fetal
development. Two types of gene-gene interactions are pos-
sible during pregnancy, intragenerational interaction, and
intergenerational interaction. Intragenerational eﬀects con-
cern gene-gene interactions within an individual’s genome
to aﬀect their own disease outcome. Intergenerational eﬀects
lead to conﬂicts between a mother and her fetus in some
casesand,inothercases,theyleadtobeneﬁcialenvironments
that protect against disease. Intergenerational interactions
can occur between genes in a child’s genome aﬀecting
the mother’s phenotype or between genes in a mother’s
genome aﬀecting the child’s phenotype. There can also be
interactions between the maternal genes and fetal genes,
such as maternal-fetal genotype incompatibility, that cause
changes in the mother’s or the child’s phenotype.
Maternal-fetal genotype (MFG) incompatibility is not
just a theoretical possibility. The most well-known example
of this form of gene-gene interaction is Rhesus factor D-
induced hemolytic disease of the newborn [1], in which a
Rhesus-negative mother develops antibodies to her Rhesus-
positive fetus, leading to destruction of fetal red blood
cells. Gene-gene interactions have also been studied as
causes of pregnancy complications such as gestational
hypertension and diabetes [2], but they have rarely been
studied as risk factors beyond pregnancy complications.
MFG incompatibility, in particular, has been reported to
play an important role in the development of a number of
disorders, including preeclampsia, preterm delivery, small-
for-gestational-age neonates, and schizophrenia. Although
genetic conﬂict has been postulated as playing a role in these
disorders, rigorous modeling and quantitative analysis of
these gene-gene interactions have only begun recently, as a
result of biotechnological developments that have made it
possible to conduct these investigations.
Researchersconductinggenome-wideassociationstudies
(GWAS) occasionally test for intragenerational gene-gene
interactions, but they seldom test for maternal genetic
inﬂuences on the phenotypes—and almost never test for
intergenerational gene-gene interactions. There are several
reasons for these omissions. First, testing for maternal
geneticinﬂuencesrequiresthatbothmothersandchildrenbe
genotyped. Very often, the father’s genotype is also required
by numerous analytical methods. This requirement increases
the number of individuals who must be genotyped and also
increases the number of tests conducted, which makes the
study expensive. Second, it may even be impossible to obtain
maternal genotypes if the disease has an adult onset.
Itisourcontentionthatlimitinggenediscoverytosingle-
gene analysis using unrelated individuals is a mistake. With
much of the genetic architecture of complex traits left unex-
plained, more investment into intergenerational gene-gene
interactions is warranted. The evidence for multiple genetic
inﬂuences during early development takes on a variety of
formsandtheeightarticleschosenforthespecialissuereﬂect
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Lupo et al. [3] examine gene-gene interactions in folate
metabolic genes as risk factors for relatively common
birth defects such as conotruncal heart defects (CTHDs),
following up on their earlier work showing that some
polymorphisms in folate metabolic genes are associated with
CTHDs when these polymorphisms are analyzed separately
[4]. In the current paper, they not only test for child
gene-gene interactions, but also for maternal gene-gene
interactions. Interestingly, their most signiﬁcant results are
observed for a maternal gene-gene interaction between
CBS844ins68 and rs1801133. Neither locus is signiﬁcantly
associated in the marginal analysis of maternal eﬀects. Given
that they also observe child allelic eﬀects, it would be
interesting to know whether there are any maternal-fetal
genotype incompatibilities.
It is natural to wonder just how widespread inter-
generational gene-gene interactions are. Is it reasonable
to suggest that maternally expressed genes or interactions
between mother’s and child’s genes represent a substantial
portion of the attributable risk of complex disease? Priest
and Wade [5] use evolutionary population genetic theory
to tackle this question. Their simulations of two unlinked
loci, one expressed maternally and the other expressed
in the child, demonstrate that maternally expressed alle-
les that increase disease susceptibility in the child can
have higher frequencies and persist longer than child
expressed alleles that increase disease susceptibility. Gene-
gene interactions between maternal and fetal genes can
lead to even greater frequency and persistence of these
ﬁtness-reducing alleles. They provide some intuition for
these results by pointing out that deleterious genes that
are expressed maternally hide out unexpressed in fathers,
and are thus partially shielded from purifying selection.
Their results also show that maternally expressed genes and
maternal-fetal gene interactions will be diﬃcult to detect in
typical linkage disequilibrium mapping study designs like
GWAS.
Many of the analytical methods designed to test for
maternal allelic eﬀects or MFG incompatibility rely on an
assumption of mating symmetry in the population. Mating
asymmetry and maternal allelic eﬀects can be confounded
in these methods [6], so it is important to have an analysis
method that is robust to mating symmetry violation when
mating asymmetry is suspected in the population. By
comparing methods through simulation, Healy et al. [7]
ﬁnd that the case-triad/case-control hybrid test performs
well under mating asymmetry. They then apply the test to
examine the association of SNPs in the promoter of cell-cycle
genes with childhood pre-B acute lymphoblastic leukemia to
ﬁnd both maternal allelic and child allelic eﬀects.
Healy et al. [7] do not directly test for maternal-fetal
genotype incompatibility. This test requires modifying the
underlying model of the case-triad/case-control hybrid test
to allow for maternal-fetal genotype interaction. In their
analysis of the association of TNF-α G308A polymorphisms
with preterm delivery (PTD), Liang et al. [8] make the
necessary modiﬁcations to a hybrid case-parent trio and
control-parent model to allow for MFG incompatibility.
Rather than limiting the analysis to a speciﬁc form of MFG
incompatibility such as HLA matching [6] or noninherited
maternal antibody eﬀects [9], they model joint maternal
and child allelic eﬀects, which requires 6 parameters for a
diallelic locus. The maternal and fetal main eﬀect model
requires only 4 parameters, so the null hypothesis of no
MFG incompatibility can be tested with a likelihood ratio
test that compares these two models without specifying the
MFG mechanism. The disadvantage of their approach is a
loss of power when the MFG incompatibility mechanism is
known and requires fewer parameters (such as the case for
RHD incompatibility).
The eﬀects of maternal-fetal genotype incompatibility
are not limited to neonatal, or even childhood, disorders. In
her review article, Palmer [10] summarizes the evidence that
MFG incompatibilities are risk factors for schizophrenia. She
alsoprovidescompellingbiologicalargumentstosupportthe
viewpointthatRHDandHLA-Bincompatibilitiesareconsis-
tent with the neurodevelopmental hypothesis of schizophre-
nia. Interestingly, the two MFG incompatibilities, which
have diﬀerent mechanisms of action but ultimately may be
risk factors because they both can lead to hypoxia, show
diﬀerent sex eﬀects. RHD incompatibility has a stronger
eﬀect in males than females and HLA-B incompatibility has
as t r o n g e re ﬀect in females than males. Palmer [10] points
out that olfactory deﬁcits in the parents of schizophrenics
may play a role in HLA-B incompatibility, and this could
certainly be true. Olfactory deﬁcits produce mating-type
frequencies for the parents of cases that are diﬀerent from
the mating-type frequencies for the parents of controls. The
MFG test is independent of the mating-type frequencies of
controls [6] and so cannot be used to test this hypothesis.
The signiﬁcant results in [11], however, cannot be explained
by this gene-environment covariation alone [12]b e c a u s e
they are the consequence of mating asymmetry to a lesser
extent and of transmission distortion to a greater extent
[6, 9, 11]. Olfactory deﬁcits in the parents should not lead
to transmission distortion.
Developmental eﬀects on adult onset, complex disease
are often far from simple in their mechanism. Perinatal
environmental eﬀects can be highly variable depending on
the child’s genetic makeup. The correlation of birth weight
to adult blood pressure has been much studied, but the
reasons for the association are unclear. Using data from
the Bogalusa Heart Study, a longitudinal prospective study
documenting cardiovascular risk factors, Chen et al. [13]
determine that the degree of association between birth
weight and age-related trends in diastolic and systolic blood
pressure is dependent on polymorphisms in beta-adrenergic
receptor genes by ﬁnding signiﬁcant three-way interactions
of β2-AR ARG16GLY, β3-AR TRP64ARG, and birth weight.
Interestingly, the main eﬀects of these genes and their two-
way interactions are not signiﬁcant.
The eﬀects of maternal fetal genotype incompatibilities
mustbemodulated byprenatalenvironment. Asanexample,
maternal infections during pregnancy have been implicated
as risk factors for disorders in children as diverse as congeni-
tal abnormalities [14], hearing loss [15], and schizophrenia
[16, 17]. Indeed there may be gene-by-maternal urinary
tract infection eﬀects in schizophrenia [18]. Thus it isJournal of Biomedicine and Biotechnology 3
important to understand the genetic risk factors underlying
recurrent urinary tract infection (UTI). Zaﬀanello et al. [19]
summarizetheresearchinto thegenetic determinants ofUTI
and ﬁnd that, of the candidate genes studied, only HSPA1B,
CXCR1, CXCR2, TLR2, TLR4, and TGF-β1 are signiﬁcantly
associated with recurrent UTI. Of these genes, CXCR1 is the
most extensively studied and supported. CXCR1 encodes the
receptor for the IL-8 chemokine [20], and chemokines are
an important part of the inﬂammatory process. The research
into the genetic basis of recurrent UTIs has only just begun,
so more work is needed to determine whether any of these 6
genes interact intra- or inter-generationally.
Nowhere is the complex interplay of maternal and fetal
genetics more intriguing than for phenotypes originating
with the placenta. Hoegh et al. [21]p r o ﬁ l eg e n ee x p r e s s i o n
of placenta tissue from women aﬀected with preeclampsia
and compare this gene expression proﬁle to the gene
expression proﬁle of placenta tissue from women whose
pregnancies were normal. Due to the relatively small sample
size, their study may be limited to those genes that show
large diﬀerences in expression; however, they still ﬁnd 21
diﬀerentially expressed genes that can be classiﬁed into a
number of roles, including placentation, oxidative stress,
inﬂammatoryresponse,andbloodpressureregulation.Their
results and earlier work implicating joint maternal and
fetal risk factors [22] suggest that a complex network of
concerted maternal-fetal gene actions is responsible for
preeclampsia.
Research into methods to detect maternal and perinatal
gene-gene interactions and to understand the mechanisms
of these interactions is just beginning. The articles in this
special issue represent a broad range of approaches and
each one provides additional evidence that these gene-gene
interactions play a signiﬁcant role in human disease. More
research is needed, however, to determine just how great an
impact maternal and perinatal gene-gene interactions have
in determining human phenotypes. It is hoped that a thor-
ough understanding of maternal and perinatal gene-gene
interaction will lead to major breakthroughs in prevention,
treatment, and therapeutics.
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